University College London

Global Experts from SEPA Call for the Control of Gingivitis Rather than Waiting for Periodontitis to Develop

Retrieved on: 
Monday, April 8, 2024
CASA, Toothpaste, Head, Confusion, Tooth brushing, EFP, Journal of Clinical Periodontology, Patient, Quality of life, Complutense University of Madrid, UCM, Therapy, Dental, Oral hygiene, Etiology, United States of Europe, Risk, Education, Gingivitis, Treatment, Recurrence, Dentistry, Prevalence, Disease, Clinical, White paper, Public, Knowledge, Research, University, Overalls, University College London, Mouthwash, Dentist, Molina Healthcare, Health, Motivation, Incidence, Physician, British Dental Journal, Inflammation, Pharmacist, Plaque, Systematic review, Bleeding, S3, Meta-analysis

SEPA: Limited knowledge among oral health teams of the recommendations and evidence currently available on oral antiseptics (that are clinically proven to be effective) reduces their implementation; therefore, more practical and simple advice is proposed.

Key Points: 
  • This was highlighted at an International Summit of Experts held at the Casa de las Encías in Madrid, Spain, the headquarters of the SEPA Foundation.
  • "Periodontal diseases are prevalent worldwide, affecting hundreds of millions of people," says the meeting coordinator, Dr. Paula Matesanz, vice president of SEPA.
  • As Dr. Iain Chapple summarizes, "It is time for a paradigm shift: we must control gingivitis and not wait until periodontitis develops."
  • J Clin Periodontol 2022 Jun:49 Suppl 24:4-71 (version adapted by SEPA available at https://portal.guiasalud.es/gpc/tratamiento-periodontitis-estadio-iv )
    * Chapple I, Time to take gum disease seriously.

OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann

Retrieved on: 
Monday, April 8, 2024
Royal, Medicine, FRS, Biochemical Society, Translational research, Wellcome Sanger Institute, Woman, Drug discovery, Trinity College, Royal Society, International, GSK, University, Membrane, Patient, Doctor of Philosophy, EMBO Gold Medal, University College London, Translation, Architecture, Therapy, Immune system, SAB, The Genetics Society, Molecular biology, Pharmaceutical industry

Oxford, United Kingdom – 8th April 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Sarah Teichmann PhD, FMedSci, FRS to its Scientific Advisory Board (SAB), effective immediately.

Key Points: 
  • Oxford, United Kingdom – 8th April 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Sarah Teichmann PhD, FMedSci, FRS to its Scientific Advisory Board (SAB), effective immediately.
  • During this time, she also collaborated with OMass’ co-founder, Professor Dame Carol Robinson, on unraveling the in vivo and in vitro assembly of soluble protein complexes.
  • Ali Jazayeri, Chief Scientific Officer at OMass Therapeutics, commented: “I look forward to working with Sarah.
  • Our previous long-standing collaboration on the assembly of soluble protein complexes demonstrates how her skillset can be complementary to our native mass spectrometry approach and can contribute to further developing our drug discovery platform.”
    Sarah Teichmann, Member of the Scientific Advisory Board of OMass Therapeutics, added: “I am thrilled to be joining OMass Therapeutics’ SAB.

TODAQ Micro Launches Micropayments and AI Conversational Checkout

Retrieved on: 
Tuesday, April 2, 2024
CIO, CDO, UCL, Recess (album), Coalition, Digital, Patient, HHS, ARM, AI, Privacy, University College London, Music, Language, TAPP, Online shopping

Toronto, Ontario, April 02, 2024 (GLOBE NEWSWIRE) -- TODAQ Micro Inc. (“TODAQ”), a micropayments pioneer, is announcing the public beta launch of TAPPTM (Tap-and-Privately-Pay) and TAPP Conversational CheckoutTM AI sales agents. TAPP is a low-code software payment product that enables instant, “one-TAPP” payments for content or services without requiring a subscription sign-up or account log-in from the customer.

Key Points: 
  • Over 100 companies are adopting the company’s pay-as-you-go one-TAPP instant payment checkout solution for digital content and services, without users needing to subscribe or login
    Toronto, Ontario, April 02, 2024 (GLOBE NEWSWIRE) -- TODAQ Micro Inc. (“TODAQ”), a micropayments pioneer, is announcing the public beta launch of TAPPTM (Tap-and-Privately-Pay) and TAPP Conversational CheckoutTM AI sales agents.
  • TAPP Conversational Checkout is a first in the AI market.
  • Historically, a $0.25 payment could easily cost $0.35 to process, rendering a segment of potential customers uneconomical to serve,” said Hassan Khan, CEO of TODAQ.
  • “This kind of instant checkout experience otherwise has only been available through Apple, Amazon, or other tech giants.

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Monday, April 1, 2024
Lewy body, Research, GBA, Administration, Plasma, Conference, MRI, DLB, GFAP, Basal forebrain, Patient, Journal, Chairperson, Sale, TID, Manuscript, Public expenditure, Biomarker, Glial fibrillary acidic protein, MD, University College London, Atrophy, Publication, Frontotemporal dementia, Alpha-synuclein, NIA, Research and development, Vertex Pharmaceuticals, Axonal transport, Dementia, CRVO

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported its financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Moreover, the neflamapimod treatment effects on GFAP were correlated to clinical outcomes, assessed by the CDR-SB.
  • Cash Position: As of December 31, 2023, CervoMed had $7.8 million in cash and cash equivalents as compared to $4.1 million as of December 31, 2022.
  • This increase was attributed to the RewinD-LB Phase 2b clinical study in DLB which began in the first quarter of 2023.
  • Net Loss: Net Loss was $2.2 million for the year ended December 31, 2023, compared to a net loss of $5.8 million for year ended December 31, 2022.

Inspired Entertainment, Inc. Appoints Simona Camilleri as General Counsel

Retrieved on: 
Tuesday, March 19, 2024
Remote, General counsel, Blockchain, Education, Knowledge, Executive Committee, University, University College London, Science, Pleasure, Commerce, Fintech, LLD, Trade, Corporation, Management

NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Inspired Entertainment, Inc. (“Inspired” or the “Company”) (NASDAQ: INSE), a leading B2B provider of gaming content, technology, hardware, and services, today announced the transition of its General Counsel position with the appointment of Simona Camilleri.

Key Points: 
  • NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Inspired Entertainment, Inc. (“Inspired” or the “Company”) (NASDAQ: INSE), a leading B2B provider of gaming content, technology, hardware, and services, today announced the transition of its General Counsel position with the appointment of Simona Camilleri.
  • Dr. Camilleri brings nearly two decades of experience to Inspired, with a strong legal background in various fields including iGaming, payments regulation, fintech, blockchain, negotiation, privacy law, mergers & acquisitions, and licensing.
  • "We are thrilled to welcome Simona as Inspired’s General Counsel.
  • Additionally, we are grateful that Carys, after twelve years of devoted service with Inspired, will continue service as Corporate Secretary.

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Retrieved on: 
Monday, March 18, 2024
DAS, Retina, University, Moorfields Eye Hospital, Pathology, Oligonucleotide, Ranibizumab, Data analysis, Partnership, Business, Boehringer Ingelheim, DME, Patient, Pharming, Research, Royal College of Ophthalmologists, Cell biology, Diabetic retinopathy, C3, University College London, MBA, Eye, Johnson & Johnson, Janssen, Drug development, John Radcliffe Hospital, AMD, CLS, University of Oxford, Royal college, Geographic atrophy, Stargardt disease, DMI, Pharmaceutical industry

ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.

Key Points: 
  • ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.
  • George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer of Clearside, commented, “Victor is a well-known and well-respected retinal clinician and scientist, who is a strategically focused and visionary leader.
  • We are delighted to have him join the Clearside team.
  • “With the upcoming ODYSSEY data and extensive partnership portfolio, this is an exciting time to join Clearside.

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Retrieved on: 
Thursday, March 14, 2024
Nucleus, Bone marrow, BCMA, BioNTech, B-ALL, Patient, ALL, SLE, Engineering, Minocycline, European Medicines Agency, Therapy, Research, Canadian Aviation Regulations, Flow cytometry, ASH, General counsel, Immunotherapy, SVP, EMA, Legal Affairs, Trial of the century, GMP, SME, BLA, Nature Communications, Development, UCL, Biologics license application, Multiple myeloma, MIA, University College London, Senior, TRBC, GD2, ASCO, FDA, CD19, Conference call, Conference, MAA, EHA, ADS, MHRA, T cell, ACS Chemical Biology, PDUFA, Autoimmune disease, Pharmaceutical industry

“For now, we remain fully focused on preparing for a potential obe-cel launch and successfully transitioning Autolus to a commercial stage company.

Key Points: 
  • “For now, we remain fully focused on preparing for a potential obe-cel launch and successfully transitioning Autolus to a commercial stage company.
  • In February 2024, Autolus promoted Dr. Chris Williams to Chief Business Officer and Alex Driggs to Senior Vice President, Legal Affairs and General Counsel.
  • Dr. Leiderman brings extensive transactional and financial expertise, and Mr. Azelby brings more than 30 years of biopharmaceutical leadership and commercial experience to Autolus’ Board.
  • Financial Results for the Year Ended December 31, 2023

3Daughters Announces Three New Appointments to Board of Directors

Retrieved on: 
Wednesday, March 13, 2024
Quotient, Thakeham, Alnylam Pharmaceuticals, CDMO, Birth, Labs, GSK plc, Pharmacy, University, Novartis, Dana–Farber Cancer Institute, IUD, University College London, Embryology, IND, MBA, Woman, Doctor of Philosophy, Intrauterine device, Therapy, Drug development, Allergan, Amersham plc, Takeda Oncology, Chief Justice of Hungary, Pharmacia, Birth control

Miles, Ph.D., and Sarah J. Stevens, Ph.D., to serve on the Company’s Board of Directors.

Key Points: 
  • Miles, Ph.D., and Sarah J. Stevens, Ph.D., to serve on the Company’s Board of Directors.
  • An IND for 3D-001 will be filed this year followed by a Phase 1 clinical trial.
  • Mary Beth Cicero, CEO of 3Daughters, expressed her enthusiasm about the new additions to the board: "We are incredibly excited to have the collective strengths of Michele, Sarah, and Vin on our Board of Directors.
  • With this first product, 3Daughters expects to disrupt the IUD market and establish a position as a major innovator in women's healthcare.

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

Retrieved on: 
Wednesday, March 13, 2024
ICST, ISCT, International Society, Disease, Science, Career Achievement Award, Patient, Knowledge, Lead, Gene, University College London, GMP, CGT, CSO, Vaccine

Boca Raton, Florida, March 13, 2024 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) (the “Company”),  a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announces its Chief Scientific Officer and Co-Founder Mark Lowdell, Ph.D. has been awarded the Career Achievement Award in Cell and Gene Therapy by the International Society of Cell & Gene Therapy (ISCT), which the organization considers its highest honor. The award was announced as part of the annual ICST Major Awards announcement. Dr. Lowdell will receive the award during the organization’s annual meeting in Vancouver on May 29, 2024.

Key Points: 
  • The award was announced as part of the annual ICST Major Awards announcement.
  • Dr. Lowdell will receive the award during the organization’s annual meeting in Vancouver on May 29, 2024.
  • The ISCT is the elite organization in the field of cell and gene therapy,” said R.J. Tesi, M.D., INmune Bio’s Chief Executive Officer.
  • “I am honored to receive this most prestigious award in recognition of my life’s work and wish to thank the members of the ISCT.

Butterfield Appoints General Counsel Following Retirement

Retrieved on: 
Friday, March 15, 2024
Banking, Asset Management, Professional Services, Finance, American Express, NTB, Cayman Islands, General counsel, Private practice, Merrill (company), Bank, University, BSX, University College London, LLM, Senior, Multimedia, Slaughter

Butterfield & Son Limited ("Butterfield" or the "Bank") (BSX: NTB.BH; NYSE: NTB) today announced the appointment of Simon Des-Etages to General Counsel and Group Chief Legal Officer effective March 18, 2024.

Key Points: 
  • Butterfield & Son Limited ("Butterfield" or the "Bank") (BSX: NTB.BH; NYSE: NTB) today announced the appointment of Simon Des-Etages to General Counsel and Group Chief Legal Officer effective March 18, 2024.
  • Mr. Des-Etages succeeds Shaun Morris, who has served in the role for the last twelve years and made the decision to retire.
  • Mr Des-Etages then moved to Merrill Lynch, where he spent eight years working as a senior counsel in the Global Private Client Group.
  • He holds a Master of Laws (LLM) from University College London and a Bachelor of Laws from the University of Essex, UK.